Please login to the form below
dermatitis
This page shows the latest dermatitis news and features for those working in and with pharma, biotech and healthcare.
As France protests, Sanofi takes axe to 670 jobs
dermatitis therapy Dupixent (dupilumab), checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi(caplacizumab) for acquired thrombotic thrombocytopenic purpura.
Latest news
-
Orphan drugs from Biogen and Amicus win UK Prix Galien
Sanofi’s treatment for moderate-to-severe atopic dermatitis Dupixent was highly commended in the same category.
-
Dupixent helps put Sanofi back on growth track
and delivered on its promise thanks to a surge in sales for atopic dermatitis drug Dupixent.
-
New data keeps AbbVie’s star pipeline therapies on track
It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... Upadacitinib is already in a phase III trial in atopic dermatitis and picked up a
-
Gilead, Galapagos JAK inhibitor clears phase II test
Like filgotinib, upadacitinib is also being tested in a string of other indications, including psoriatic arthritis, Crohn’s disease, ulcerative colitis and atopic dermatitis.
-
AZ, Amgen’s first-in-class asthma drug gets breakthrough status
Regeneron’s new candidate Dupixent (dupilumab), an IL-4 and IL-13 inhibitor that is already approved for atopic dermatitis.
More from news
Approximately 8 fully matching, plus 55 partially matching documents found.
Latest Intelligence
-
Leo has its eyes on the prize
Psoriasis and dermatitis may seem the same in everybody but maybe the picture is more like it is in cancer where you have subsets. ... Bridging the gap. Leo is tracking increases in atopic dermatitis across Europe while psoriasis levels show no signs of
-
Pharma deals continue to slide
Phase II MAb to block IL-13 for treatment of atopic dermatitis.
-
Deal Watch September 2016
as well as other autoimmune disorders plus VTP-38543 for atopic dermatitis.
-
Deal Watch July 2016
AstraZeneca is developing tralokinumab for severe asthma, where it is in phase III development, and has recently completed a phase IIb study in patients with atopic dermatitis.
-
Allergies and asthma
Early prevention is recommended . Allergic diseases (eg food allergies, rhinitis, asthma, atopic dermatitis) usually start in childhood but can develop at any age. ... of the hypo-allergenic milk formula on cow's milk allergy and atopic dermatitis (AD).
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
Dr Desiree Luthman joins Verona Pharma
atopic dermatitis in the US.
-
Ziarco appoints Mike Grey to board of directors
Concerning his appointment, Grey said: “I am delighted to join Ziarco's board, as the company has a strong leadership team and promising lead compounds for the treatment of atopic dermatitis
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Research Partnership launches new patient Living with Atopic Dermatitis (US) 2017 report
Living with Atopic Dermatitis (AD) is a study conducted amongst 100 adults and 50 caregivers in the US.
-
Research Partnership has published a new patient Living with Atopic Dermatitis (US) report
Living with Atopic Dermatitis (AD) is a report based on a new study conducted amongst adult sufferers and parents of child sufferers. ... An attitudinal segmentation is included to help identify the unique groups of patients Atopic Dermatitis.
-
Atopic Dermatitis — Going Beyond the Pill
Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring
-
Bringing sufferers out of the shadows – Reducing the emotional impact of living with Atopic Dermatitis
Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring
-
Research Partnership
Atopic Dermatitis — Going Beyond the Pill.
More from PMHub
Approximately 4 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Account Manager
-
Negotiable
- Senior Account Executive with progression to Account Manager, Me...
-
Excellent package
- CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...
-
EXCELLENT DAY RATES AVAILABLE
- Account Manager- Healthcare Advertising
-
Negotiable
-
Systematic Reviewer - Oxford
-
Negotiable
- Manager - Immunology, Therapeutic Area Communications & Publ...
-
Competitive Salary Offered
-
Experienced Medical Writers
-
Competitive Salary and Benefits
-
Medical (Scientific) Director
-
£120, 000 benefits
-
Business Director
-
Competitive Salary Offered
-
Associate Director
-
£75, 000-90, 000
-
Associate Medical Director
-
Excellent PTO, bonus and 401k package
-
Medical Writer
-
Salary TBC
-
Senior Account Manager
-
Competitive Salary Offered
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Principal Health Economist - North-West
-
Negotiable
-
Account Manager / Account Director
-
Competative
- Business Development Director – Health Education
-
excellent commission
Subscribe to our email news alerts
PMHub
Research Partnership
We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...
Latest intelligence
- AstraZeneca’s oncology renaissance
- Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
- Navigating the antibiotic resistance crisis
- Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
- Combined immunotherapies – potential and pitfalls
- ‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Quick links
Infographics
